Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Orlando, Florida 32804


Purpose:

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.


Criteria:

Inclusion Criteria: - Locally advanced or metastatic HCC - Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib. - Child-Pugh Class A or B (score 7 only) disease. Exclusion Criteria: - Prior treatment of advanced HCC with more than one prior first-line systemic therapy. - Any prior local therapy within 2 weeks of starting the study treatment. - Presence of hepatic encephalopathy and/or clinically relevant ascites. - Presence of main portal vein invasion by HCC.


NCT ID:

NCT01210495


Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer


Backup Contact:

N/A


Location Contact:

Orlando, Florida 32804
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.